XBiotech grants co-CEO Jan-Paul Simard 2M stock options

One-sixth vests 180 days after the grant and another one-sixth every six months thereafter, subject to the Executive Employment Agreement.

Rhea-AI Filing Summary

XBiotech Inc. granted Co-Chief Executive Officer Jan-Paul Simard 2,000,000 stock options to purchase common stock on October 26, 2026, under the 2025 Equity Incentive Plan; following the grant, he directly held 2,000,000 options. The options carry a $1.85-per-share exercise price and expire October 26, 2036. One-sixth vest on the 180th day after the grant, with an additional one-sixth vesting every six months thereafter, subject to the Executive Employment Agreement.

Insider Trade Summary

Grant/Award: 2,000,000 shares

Grant/Award 1 txn

Insider Simard Jan-Paul

Role Co-Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	2,000,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 2,000,000 contracts (Direct)

Key Figures

Stock options granted: 2,000,000 options Exercise price: $1.85 per share Initial vesting installment: 1/6 of the options +3 more

6 metrics

Stock options granted 2,000,000 options Granted to Co-Chief Executive Officer Jan-Paul Simard on October 26, 2026

Exercise price $1.85 per share Options to purchase common stock

Initial vesting installment 1/6 of the options Vests on the 180th day after the grant

First vesting milestone 180th day after October 26, 2026 Initial one-sixth installment

Subsequent vesting interval Every six months An additional one-sixth vests at each interval

Option expiration date October 26, 2036 Options expire ten years after the grant date

Key Terms

exercise price, vest, 2025 Equity Incentive Plan

3 terms

exercise price financial

"at an exercise price equal to the Nasdaq closing price on the Grant Date"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"One-sixth (1/6) of the Options vest on the 180th day"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

2025 Equity Incentive Plan financial

"under the Company's 2025 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did XBIT’s co-CEO receive, and at what exercise price?

Jan-Paul Simard received 2,000,000 stock options to purchase common stock on October 26, 2026, at an exercise price of $1.85 per share.

What is the vesting schedule for XBIT’s co-CEO’s options?

One-sixth of the options vests on the 180th day after the October 26, 2026 grant date, with an additional one-sixth vesting every six months thereafter, subject to the Executive Employment Agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 03:32 PM EDT Accepted by SEC EDGAR 10/28/2026 - 03:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simard Jan-Paul

(Last) (First) (Middle)

5217 WINNEBAGO LN, AUSTIN, TX 78744

(Street)

AUSTIN TEXAS 75013

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
XBiotech Inc. [ XBIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.85	10/26/2026		A		2,000,000		04/24/2027	10/26/2036	Common Stock	2,000,000	$0	2,000,000	D

Explanation of Responses:

Remarks:

On October 26, 2026 (the "Grant Date"), the reporting person was granted options to purchase 2,000,000 shares of the Company's common stock under the Company's 2025 Equity Incentive Plan, at an exercise price equal to the Nasdaq closing price on the Grant Date. The Options expire ten years after the Grant Date. One-sixth (1/6) of the Options vest on the 180th day following the Grant Date, with an additional one-sixth (1/6) vesting every six months thereafter, subject to the terms of the Executive Employment Agreement.

	Jan-Paul Simard	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)